q4 non-gaap earnings per share $3.28.
q4 revenue rose 11 percent to $759.1 million.
initiating fiscal year 2022 guidance.
sees fiscal 2022 non-gaap diluted earnings per share $13.60 - $14.00.
fiscal year 2022 guidance does not include generate life sciences acquisition.
